Provided by Tiger Fintech (Singapore) Pte. Ltd.

Academy Sports & Outdoors, Inc.

37.98
-1.9300-4.84%
Volume:255.00K
Turnover:9.76M
Market Cap:2.54B
PE:6.63
High:39.66
Open:38.63
Low:37.41
Close:39.91
Loading ...

Vanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"

PR Newswire
·
24 Feb

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

Benzinga
·
19 Feb

Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results

PR Newswire
·
14 Feb

ASO International Inc. Reports Strong Half-Year Financial Performance

TIPRANKS
·
13 Feb

Is Academy Sports and Outdoors, Inc. (ASO) the Best Gun Stock to Buy in 2025?

Insider Monkey
·
13 Feb

CAMP4 to Participate in Upcoming Investor Conferences

GlobeNewswire
·
06 Feb

Torque Metals and Aston Minerals Advance Merger with Key Appointments and Terms Finalization

TIPRANKS
·
30 Jan

Aston Minerals and Torque Metals Announce Strategic Merger to Enhance Gold Exploration

TIPRANKS
·
28 Jan

Academy Sports and Outdoors, Inc. (ASO): A Bull Case Theory

Insider Monkey
·
23 Jan

Academy Sports (ASO): Buy, Sell, or Hold Post Q3 Earnings?

StockStory
·
13 Jan

Press Release: Praxis Precision Medicines Highlights 2025 Corporate Strategy and Business Priorities

Dow Jones
·
13 Jan

Academy Sports ready to pop after disastrous year, Barron’s says

TIPRANKS
·
12 Jan

Academy Sports Is Ready to Rebound -- Barron's

Dow Jones
·
11 Jan

Investors Will Want Academy Sports and Outdoors' (NASDAQ:ASO) Growth In ROCE To Persist

Simply Wall St.
·
11 Jan

Academy Sports & Outdoors Is Maintained at Hold by TD Cowen

Dow Jones
·
09 Jan

After a Disastrous Year, This Retailer's Stock Looks Ready to Pop -- Barrons.com

Dow Jones
·
08 Jan

CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones

GlobeNewswire
·
08 Jan

Loop Capital encouraged by price competitiveness at Academy Sports

TIPRANKS
·
07 Jan

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Business Wire
·
07 Jan

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Business Wire
·
07 Jan